Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Targeting angiogenesis in oncology].

J Fayette1, J-C Soria, J-P Armand

  • 1Département de médecine, institut Gustave-Roussy, Villejuif, France. jfayette@9online.fr

Pathologie-Biologie
|June 7, 2006
PubMed
Summary

New drugs targeting tumor angiogenesis, the process of new blood vessel formation, are in development. By inhibiting key molecular mediators like VEGF, these therapies aim to reduce tumor size by causing neovessel death.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

ESMO open·2026
Same author

Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?

ESMO open·2023
Same author

Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.

ESMO open·2023
Same author

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Intervention strategies for microbial therapeutics in cancer immunotherapy.

Immuno-oncology technology·2022

Area of Science:

  • Molecular biology
  • Oncology
  • Biochemistry

Context:

  • Tumor growth is critically dependent on angiogenesis, the formation of new blood vessels.
  • Tumor cells release growth factors, such as vascular endothelial growth factor (VEGF), to stimulate endothelial cells.
  • This process is a key target for anti-cancer drug development.

Purpose:

  • To review the molecular mechanisms of angiogenesis in tumor growth.
  • To describe various angiogenesis inhibitors currently in clinical development.
  • To highlight the diverse mechanisms of action of these anti-angiogenic compounds.

Summary:

  • Advances in biological understanding have elucidated the molecular pathways governing angiogenesis.
  • VEGF-mediated signaling activates endothelial cells, promoting neovascularization essential for tumor expansion.
  • Several drugs in clinical trials target these molecular mediators, aiming to induce neovessel death and reduce tumor mass.

Impact:

  • Provides a comprehensive overview of anti-angiogenic strategies for cancer therapy.
  • Highlights the potential of targeting tumor angiogenesis for effective cancer treatment.
  • Informs researchers and clinicians about the diverse landscape of angiogenesis inhibitors.

Related Experiment Videos